Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy

Oncogene volume 25, pages 981–989 (2006)Cite this article

Abstract

A total of 30–50% of early breast cancer (EBC) patients considered as high risk using standard prognostic factors develop metastatic recurrence despite standard adjuvant systemic treatment. A means to better predict clinical outcome is needed to optimize and individualize therapeutic decisions. To identify a protein signature correlating with metastatic relapse, we performed surface-enhanced laser desorption/ionization–time of flight mass spectrometry profiling of early postoperative serum from 81 high-risk EBC patients. Denatured and fractionated serum samples were incubated with IMAC30 and CM10 ProteinChip arrays. Several protein peaks were differentially expressed according to clinical outcome. By combining partial least squares and logistic regression methods, we built a multiprotein model that correctly predicted outcome in 83% of patients. The 5-year metastasis-free survival in ‘good prognosis’ and ‘poor prognosis’ patients as defined using the multiprotein index were strikingly different (83 and 22%, respectively; P<0.0001, log-rank test). In a multivariate Cox regression including conventional pathological factors and multiprotein index, the latter retained the strongest independent prognostic significance for metastatic relapse. Major components of the multiprotein index included haptoglobin, C3a complement fraction, transferrin, apolipoprotein C1 and apolipoprotein A1. Therefore, postoperative serum protein pattern may have an important prognostic value in high-risk EBC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH et al. (2002a). Cancer Res 62: 3609–3614.

  • Adam B-L, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH et al. (2002b). Cancer Res 62: 3609–3614.

  • Ahmed N, Barker G, Oliva KT, Hoffmann P, Riley C, Reeve S et al. (2004). Br J Cancer 91: 129–140.

  • Antoniadis A, Lambert-Lacroix S, Leblanc F . (2003). Bioinformatics 19: 563–570.

  • Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C et al. (2005). Cancer Res 65: 2170–2178.

  • Bertucci F, Nasser V, Granjeaud S, Eisinger F, Adelaide J, Tagett R et al. (2002). Hum Mol Genet 11: 863–872.

  • Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT et al. (2004). Anticancer Res 24: 1031–1038.

  • Bonadonna G, Zambetti M, Valagussa P . (1995). JAMA 273: 542–547.

  • Carlevaro MF, Albini A, Ribatti D, Gentili C, Benelli R, Cermelli S et al. (1997). J Cell Biol 136: 1375–1384.

  • Cavanaugh PG, Jia L, Zou Y, Nicolson GL . (1999). Breast Cancer Res Treat 56: 203–217.

  • Cavanaugh PG, Nicolson GL . (1998). J Cell Physiol 174: 48–57.

  • Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK . (1993). J Clin Invest 91: 977–985.

  • Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al. (2003). J Clin Oncol 21: 1431–1439.

  • Clark EA, Golub TR, Lander ES, Hynes RO . (2000). Nature 406: 532–535.

  • Cox DR . (1972). J R Stat Soc [B] 34: 187–220.

  • De Kleijn DPV, Smeets MB, Kemmeren PPCW, Lim SK, van Middelaar BJ, Velema E et al. (2002). FASEB J 16: 1123–1125.

  • Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G . (1997). Ann Oncol 8: 1075–1080.

  • Diamandis EP . (2004). J Natl Cancer Inst 96: 353–356.

  • EBCTCG (1998). Lancet 352: 930–942.

  • Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E . (1989). Cancer Res 49: 1996–2001.

  • Fung ET, Thulasiraman V, Weinberger SR, Dalmasso EA . (2001). Curr Opin Biotechnol 12: 65–69.

  • Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY et al. (2005). Int J Cancer 115: 783–789.

  • Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn H-J . (2003). J Clin Oncol 21: 3357–3365.

  • Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP et al. (1999). Science 286: 531–537.

  • Heimann R, Hellman S . (2000). Eur J Cancer 36: 1631–1639.

  • Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al. (2003). J Clin Oncol 21: 976–983.

  • Inoue T, Cavanaugh PG, Steck PA, Brunner N, Nicolson GL . (1993). J Cell Physiol 156: 212–217.

  • Kaplan EL, Meier P . (1958). J Am Stat Assoc 53: 457–481.

  • Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S et al. (2004). Clin Cancer Res 10: 860–868.

  • Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA et al. (2003). Proc Natl Assoc Sci 100: 12343–12348.

  • Kwak J-Y, Ma T-Z, Yoo M-J, Hee Choi B, Kim H-G, Kim S-R et al. (2004). Exp Hematol 32: 836–842.

  • Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C et al. (2002). Proc Am Soc Clin Oncol 21: 36a (Abstract 141).

  • Nguyen DV, Rocke DM . (2002a). Bioinformatics 18: 1216–1226.

  • Nguyen DV, Rocke DM . (2002b). Bioinformatics 18: 39–50.

  • Nicolson GL, Cavanaugh PG, Inoue T . (1992). J Natl Cancer Inst Monogr 13: 153–161.

  • NIH (2001). J Natl Cancer Inst 93: 979–989.

  • Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. (2004). N Engl J Med 351: 2817–2826.

  • Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C et al. (2004). Hepatology 41: 40–47.

  • Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. (2000). Nature 406: 747–752.

  • Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. (2002a). Lancet 359: 572–577.

  • Petricoin III EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA et al. (2002b). J Natl Cancer Inst 94: 1576–1578.

  • Pupa SM, Menard S, Forti S, Tagliabue E . (2002). J Cell Physiol 192: 259–267.

  • Rozanov DV, Savinov AY, Golubkov VS, Postnova TI, Remacle A, Tomlinson S et al. (2004). J Biol Chem 279: 46551–46557.

  • Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT et al. (2003). Proteomics 3: 601–609.

  • Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M et al. (2003). The Lancet 362: 527–533.

  • Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A et al. (2004). Lab Invest 84: 845–856.

  • van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al. (2002). N Engl J Med 347: 1999–2009.

  • van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Bernards R et al. (2003). Breast Cancer Res 5: 57–58.

  • Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D et al. (2003). Clin Breast Cancer 4: 203–209.

  • Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack Jr BC et al. (2004). Clin Cancer Res 10: 1625–1632.

  • Zhang Z, Bast Jr RC, Yu Y, Li J, Sokoll LJ, Rai AJ et al. (2004). Cancer Res 64: 5882–5890.

Download references

Acknowledgements

We thank Dr Françoise Birg and Dr Claude Mawas for their support. This project is funded by Institut Paoli-Calmettes and INSERM. This work was supported by la Ligue Nationale Contre le Cancer (Labels to DB and JPB) and Ministries of Health and Research (Cancéropôle PACA).

Author information

Authors and Affiliations

  1. Department of Molecular Pharmacology, Institut Paoli-Calmettes, UMR599 Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France

    A Gonçalves & J-P Borg

  2. Department of Medical Oncology, Institut Paoli-Calmettes, UMR599 Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France

    A Gonçalves, F Bertucci, D Maraninchi & P Viens

  3. University of la Méditerranée, UFR of Médecine, Marseille, France

    A Gonçalves, F Bertucci, D Maraninchi & P Viens

  4. Biostatistic Department, Institut Paoli-Calmettes, UMR599 Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France

    B Esterni & V J Bardou

  5. Department of Molecular Oncology, Institut Paoli-Calmettes, UMR599 Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France

    F Bertucci, R Sauvan & D Birnbaum

  6. Biological Resource Center, Institut Paoli-Calmettes, UMR599 Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France

    C Chabannon

  7. Ciphergen Biosystems, Fremont, CA, USA

    M Cubizolles, X-Y Meng & E T Fung

  8. Surgical Oncology, Institut Paoli-Calmettes, UMR599 Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France

    G Houvenaegel

  9. Department of Pathology, UMR599 Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France

    J Jacquemier

  10. TAGC, INSERM-ERM 206, Marseille, France

    S Granjeaud

Authors
  1. A Gonçalves
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Esterni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Bertucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Sauvan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Cubizolles
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V J Bardou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Houvenaegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Jacquemier
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Granjeaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. X-Y Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E T Fung
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. D Birnbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D Maraninchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. P Viens
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J-P Borg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Gonçalves.

Additional information

Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gonçalves, A., Esterni, B., Bertucci, F. et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25, 981–989 (2006). https://doi.org/10.1038/sj.onc.1209131

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209131

Keywords

This article is cited by

Search

Advanced search

Quick links